In this episode, we chat with David Harder, the Co-Founder and Co-CEO of ATMA Journey Centers, about their new healing and training space.
Similar Posts
Juan Pablo Cappello – “We’re NOT a Psychedelics Company, We’re a Mental Wellness Company” | Nue.Life
In today’s sneak peek we see Juan Pablo Capello, co-founder…
Interview With Michelle Janikian, Author, Host & Editor at Psychedelics Today
Michelle opens up about how her work as a cannabis writer led her down the path of psychedelics, her interest in safe magic mushroom use and why she was compelled to write her guidebook Your Psilocybin Mushroom Companion.
Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!
Compass Pathways is launching a NEW Phase II clinical trial to treat PTSD!!!
The trial will use Comp 360, the company’s synthetic, proprietary version of psilocybin, in conjunction with therapy. This is Compass’ second major trial using Comp 360. They also are using it to treat Treatment Resistant Depression.
On October 3rd, 2021, Compass Pathways (Nasdaq: CMPS) announced the launch of a brand new psychedelic therapy clinical trial, using Psilocybin, the active ingredient in magic mushrooms, to treat PTSD.
The Phase 2 clinical trial will use Comp 360, Compass Pathways’ proprietary, synthetic, cristalline Psilocybin. It will be paired with talk psychotherapy in 20 adults who suffered trauma as an adult, resulting in PTSD.
While using psychedelics for mental health may seem controversial, when it comes to the science, psychedelics like psilocybin and MDMA, when paired with therapy have been shown to work.
For example, recently MAPS completed a Phase III clinical trial using MDMA therapy to treat PTSD, which showed 67% of people improving so much they no longer qualified to be diagnosed as having PTSD (cured?). Another 21% of people improved significantly.
This Compass Pathways trial is exciting, because once it is complete, we will be able to compare the results of their psilocybin trial to MAPS’ MDMA trial, to start to have an understanding of which psychedelic compound works better for treating PTSD.
This news comes as we are waiting for the results of Compass Pathways’ Phase 2b Clinical Trial, testing treating Treatment-Resistant Depression with Comp 360, to be released before the end of the year.
The results of the trial will be significant, as it will be the largest ever clinical trial studying psychedelics, with 216 patients. It will also be the most advanced clinical trial studying psilocybin, being in phase 2b.
In sum, these are very exciting times to be watching Compass Pathways. Controversies surrounding their patents aside, Compass is one of the companies pushing the frontiers of psychedelic medicines, which is very exciting to watch.
Do you think psilocybin assisted therapy could treat PTSD? Let us know in the comments.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #Psychedelics #CMPS
The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]
Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.
P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html
Time Stamps
0:00​ – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed​​ ​ #MindmedStock​​ #PsychedelicStocks
Can Ketamine Treat Depression? Meet Delic, the LARGEST Ketamine Clinic Company
In today’s episode, I talk with Matt Stang, CEO of Delic Corp. Delic (OTCMKTS: DELCF) is a psychedelic medicines company aiming to put a dent in the mental health crisis.
They are doing this in three ways.
First, through their ketamine clinics. Delic runs the largest ketamine network in the world, with dozens of clinics across North America. At the moment, these clinics are only providing ketamine therapy for disorders like depression, but in the future, once they become legal, Delic also plans on offering other psychedelic therapies such as psilocybin and MDMA therapy.
Second, through education. Delic runs multiple media platforms, such as RealitySandwich.com. These media platforms aim to educate and entertain, leading towards the destigmatization of psychedelics in our culture. As many of the people behind Delic Corp were behind the legendary High Times Magazine, this is an area of expertise for the company. Ultimately, psychedelic compounds will never succeed as medicines if society does not get behind them. Delic also has podcasts, and they host psychedelic medicine events.
And third, through science. Delic Labs is currently working on creating next generation psychedelics. Delic Labs also works with third parties, completing research, which allows the labs to run on a profit.
Taken together, Delic is not only a core player in the psychedelics movement, but they are also one of the companies making a solid revenue.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Video editing: @themyaholy @Psy_holy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. Psychedelic Spotlight and The Psychedelic Investor were hired for this video, on December 3rd, 2021, to publicly disseminate information about (DELIC CORP) via digital communications. We have been paid ($2000 CAD).
#Delic #Psychedelics #Ketamine
Does Microdosing Mushrooms Work? ( Interview with Sena Maria)
Hello Psychedelic Investors! The topic of today’s video is “Does microdosing mushrooms work?” We usually talk about investing in psychedelic stocks and companies inspired by microdosing psychedelics with the mission to cure depression, anxiety, adhd, etc. But we never really dove deep into the science of microdosing. Does Microdosing Magic Mushrooms really work? So before investing in companies like MindMed (MMED/MMEDF), Compass Pathways (CMPS), Numi, Field Trip Health (FTRP) or Atai Life Sciences, listening to someone who’s got a personal experience with psychedelics might not be such a bad idea.
One of the reasons behind the interview with pro in the Microdosing psilocybin realm is that recent studies have shown that the benefits of microdosing can be attributed completely to placebo effects. That’s why I decided to have a talk with Sena Maria. Sena is passionate about working with the fungi realm to support our collective evolution. Coming from Google in Silicon Valley she took a big life pivot and has spent the last 5 years learning from the plants. After supporting hundreds of people in getting started with microdosing, she now shares what she’s learned on her YouTube channel The Medicine of Being Human and her instagram @sena__maria.
So what do you guys think? Is Microdosing Psychedelics the Future of Medicine? Hopefully some of the new MMED or CMPS or any other psychedelic stocks investors got some value in this! What do you guys think?
You can learn more about microdosing in her popular webinar Microdosing For Resilience at www.medicineofbeinghuman.com
Timestamps:
0:00 – Intro
1:11 – What is Microdosing & How does it Work?
2:55 – Microdosing Benefits
7:28 – Why Microdosing? ( Regimen & Protocols)
14:12 – Discussing microdosing & placebo effects
19:21 – Personal Microdosing Experiences & Consistency
24:09 – Microdosing Advice for Beginners
#PsychedelicStocks #MindMed #MicrodosingPsilocybin
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.